Design, synthesis and evaluation of alpha lipoic acid derivatives to treat multiple sclerosis-associated central neuropathic pain
Bioorg Med Chem. 2022 Sep 1;69:116889.
Multiple sclerosis-associated central neuropathic pain (MS-CNP) is difficult to alleviate with clinically used pain-killers and so there is a large unmet medical need for novel treatments for alleviating MS-CNP. Although (R)-alpha lipoic acid (ALA) evoked significant pain relief efficacy in a mouse model of multiple sclerosis-associated central neuropathic pain (MS-CNP), this dietary supplement has poor oral bioavailability due to low gastric stability. Eight ester prodrugs of the R enantiomer of ALA [(R)-ALA] were designed encompassing a range of biocompatible hydrophobic and hydrophilic features and synthesized in an effort to identify a prodrug candidate that was stable at gastric and upper gastrointestinal tract (GIT) pH, and that could be released (hydrolyzed by esterases) in the blood to (R)-ALA immediately after absorption into the portal vein (i.e., highly desirable features for pain relief development). These biocompatible hydrophobic and hydrophilic (R)-ALA pro-dugs underwent comprehensive preliminary screening to reveal PD-ALA4 HCl salt (10) as a promising candidate and PD-ALA 7 (8) could be a viable substitute, utilizing enzyme-free gastric and intestinal stability assessments, LogP evaluations, in vitro plasma stability and caco-2 cell monolayer permeability.
Lipoic Acid treats MS neuropathic pain
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1478 Views
-
Last post by NHE
-
- 1 Replies
- 1152 Views
-
Last post by DIM
-
- 3 Replies
- 1425 Views
-
Last post by NHE
-
- 0 Replies
- 2754 Views
-
Last post by NHE
-
- 0 Replies
- 1143 Views
-
Last post by NHE
-
- 2 Replies
- 1441 Views
-
Last post by DIM
-
- 0 Replies
- 1198 Views
-
Last post by NHE
-
- 4 Replies
- 372 Views
-
Last post by ElliotB
-
- 0 Replies
- 1917 Views
-
Last post by NHE